1073612-91-5

中文名稱 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸

英文名稱 CY-09

CAS 1073612-91-5

分子式 C19H12F3NO3S2

分子量 423.43

MOL 文件 1073612-91-5.mol

更新日期 2026/07/29 14:31:53

1073612-91-5 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸價(jià)格(試劑級(jí)) 常見問題列表

基本信息

中文別名

化合物CY09
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
4-((4-氧代-2-硫代-3-(3-(三氟甲基)芐基)噻唑烷-5-亞基)甲基)苯甲酸

英文別名

CY-09
CS-2756
CY 09
CY09
CY09
CY 09
CY-09
4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid
(E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid
4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid
Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]-

物理化學(xué)性質(zhì)

沸點(diǎn)559.574±60.00 °C(Press: 760.00 Torr)(predicted)

密度1.567±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

儲(chǔ)存條件-20°C儲(chǔ)存

溶解度DMSO:65.0(Max Conc. mg/mL);152.61(Max Conc. mM)

酸度系數(shù)(pKa)3.878±0.10(predicted)

形態(tài)結(jié)晶固體

顏色Light yellow to yellow

InChI1S/C19H12F3NO3S2/c20-19(21,22)14-3-1-2-12(8-14)10-23-16(24)15(28-18(23)27)9-11-4-6-13(7-5-11)17(25)26/h1-9H,10H2,(H,25,26)/b15-9+

InChIKeyDJTINRHPPGAPLD-OQLLNIDSSA-N

SMILESOC(C(C=C1)=CC=C1/C=C(SC2=S)\C(N2CC3=CC=CC(C(F)(F)F)=C3)=O)=O

安全數(shù)據(jù)

WGK GermanyWGK 3

存儲(chǔ)類別11 - Combustible Solids

圖譜信息

4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸(1073612-91-5)核磁圖(¹HNMR)

4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/07/06	S5774	4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸 CY-09	1073612-91-5	5mg	1204.51元
2026/07/06	S5774	4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸 CY-09	1073612-91-5	10mM (1mL in DMSO)	1367.73元
2026/07/06	S5774	4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸 CY-09	1073612-91-5	25mg	3849.84元

常見問題列表

生物活性

CY-09是一種特異的NLRP3 inflammasome的抑制劑，直接靶向NLRP3。它對(duì)5種主要的cytochrome P450酶的IC50值分別為18.9, 8.18, >50, >50 和 26.0 μM。

靶點(diǎn)

Target	Value
NLRP3 inflammasome ()

體外研究

CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 specifically inhibits NLRP3 inflammasome activation and has no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization.

體內(nèi)研究

CY-09 treatment in vivo efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation in vivo . CY-09 treatment also increases the survival of NLRP3 mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of high-fat diet (HFD)-treated mice is also suppressed by CY-09.